On September 4, 2018 Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ: EGRX) reported that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the Morgan Stanley 16th Annual Global Healthcare Conference as follows (Press release, Eagle Pharmaceuticals, SEP 4, 2018, View Source [SID1234529441]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Thursday, September 13, 2018
Time: 4:05 p.m. Eastern Daylight Time
Location: Grand Hyatt New York, NYC
Webcast:

https://cc.talkpoint.com/morg007/091218a_as/?entity=53_0XGPDH2

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.eagleus.com, under the Investors + News Section.

On September 4, 2018 LifeArc, one of the UK’s leading medical research charities, is delighted to announce the appointment of Melanie Lee, PhD, CBE as its new Chief Executive Officer (CEO), effective 1st November 2018 (Press release, LifeArc, SEP 4, 2018, View Source [SID1234529465]). Dave Tapolczay, the present CEO, will be retiring from his position next month after 11 years’ service.1 Melanie brings to LifeArc a wealth of leadership experience from the biopharmaceutical industry and the medical research charity sector. Her previous role as Chief Scientific Officer of BTG plc followed senior research leadership positions at Glaxo/GlaxoWellcome, Celltech plc / UCB; Non-Executive Director roles at H. Lundbeck A/S and BTG plc and currently at Sanofi, CEO roles at Syntaxin Ltd and NightstaRx Ltd and Chair and Deputy Chair Trustee appointments at Cancer Research Technology and Cancer Research UK respectively.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Explaining her reasons for accepting the CEO role Melanie said: "This is a once in a lifetime opportunity for me to join a unique charity that can create life-changing therapeutics. The innovative scientific research supported by LifeArc encompasses numerous life science sectors and has the potential to deliver great science, innovative medicines and new diagnostics to patients in need; it’s this potential that really motivates me. I am looking forward to the prospect of leading this vibrant research charity through the next phase of its development."

Melanie’s appointment has been made at a time of great opportunity for LifeArc. The charity, which evolved from Medical Research Council Technology (MRCT) in 2017, has benefitted from a significant royalty stream arising from sales of Keytruda.2 The income stream generated by Keytruda and other projects, has transformed LifeArc’s ability to fund and invest in innovative medical research and has already resulted in the creation of a dedicated Seed Fund and of a Philanthropic Fund providing rare disease research grant funding.

Commenting on the announcement, Dr John Stageman, OBE, LifeArc’s Chair, said: "We conducted a detailed and lengthy search for our new CEO and my fellow Trustees and I are delighted that Melanie has decided to join us at this most exciting time in the organisation’s history. I believe that she possesses the ideal blend of business leadership plus strategic and scientific acumen to help us deliver a bright future for LifeArc. With the addition of Melanie’s unique professional experience to our already-established senior executive team, I am confident that LifeArc can continue to evolve by turning great science into greater patient benefit."

On September 4, 2018 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, reported its Phase II clinical trial of drug candidate Namodenoson (CF102) for the treatment of advanced hepatocellular carcinoma (HCC) in patients whose disease has progressed on sorafenib therapy (Press release, Can-Fite BioPharma, SEPT 4, 2018, View Source [SID1234529260]). Top line efficacy results are expected by end of year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The global Phase II study is being conducted in the U.S., Europe and Israel. Patients with advanced HCC, Child Pugh B, who failed Nexavar (sorafenib) as a first line treatment are treated twice daily with 25 mg of oral Namodenoson or placebo using a 2:1 randomization. The primary endpoint of the Phase II study is Overall Survival (OS). Secondary endpoints include Progression Free Survival (PFS), safety, and the relationship between outcomes and A3AR expression.

Advanced liver cancer is categorized into 3 subclasses including Child Pugh A, mostly treated with Nexavar, Child Pugh B and Child Pugh C. Although a few drugs for the treatment of advanced liver cancer have recently launched, none are specifically aimed at treating patients who have reached the Child Pugh B stage. This represents a major unmet need and potentially positions Namodenoson as an important drug candidate to treat this patient population.

Enrollment of 78 patients was completed in August 2017. While the trial continues treating subjects in a blinded fashion (either Namodenoson 25 mg BID or matching placebo), Can-Fite notes that of the 78 subjects originally enrolled, 22 completed at least 12 cycles of treatment (each cycle is 28 days of treatment), of whom 5 completed 24 cycles. The longest-treated subject has been receiving study medication for over 3 years.

Accumulated safety data to date continues to indicate a favorable safety profile, with no clinically significant novel or emerging events attributed to chronic treatment with Namodenoson.

Can-Fite’ CEO, Dr. Pnina Fishman, commented, "We are pleased with the progress so far in our clinical trial for Namodenoson for the treatment of advanced HCC, the third leading cause of cancer deaths worldwide, and look forward to data release. We believe a major advantage of Namodenoson stems from its favorable safety profile demonstrated thus far, in which Namodenoson selectively targets diseased cells while sparing normal cells which express very low levels of the A3 receptor.

Can-Fite received Orphan Drug Designation for Namodenoson in Europe and the U.S., as well as Fast Track Status in the U.S. as a second line treatment for HCC.

About Namodenoson

Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson is being evaluated in Phase II trials for two indications, as a second line treatment for hepatocellular carcinoma, and as a treatment for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug.

On September 4, 2018 Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a Fortress Biotech (NASDAQ: FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene therapies for rare diseases, reported oral and poster presentations related to its CAR T therapies at the 4th Annual CAR-TCR Summit 2018, to be held September 4-7,2018, at the Seaport Hotel & World Trade Center in Boston (Press release, Mustang Bio, SEP 4, 2018, View Source [SID1234529307]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the oral presentations are as follows:
Title: Confronting Analytical Challenges of Chimeric Antigen Receptor T Cell
Presenter: Junxia Wang, M.D., Ph.D., Director of Analytical Development, Mustang Bio
Track: Manufacturing
Date and Time: Tuesday, September 4, 2018, 3 p.m. EDT

Title: CAR T Cell Therapy for Glioblastoma: Progress, Promises and Challenges
Presenter: Behnam Badie, M.D., Professor and Chief, Division of Neurosurgery & Director, Brain Tumor Program,
City of Hope Medical Center
Track: Focus Day: Overcoming CAR T Toxicity in Solid Tumors
Date and Time: Friday, September 7, 2018, 12 p.m. EDT

Title: CAR T cells and Combination Therapies: The Next Chapter of the Immuno-Oncology Revolution
Panelist: Ekta Patel, Ph.D., Associate Director of Translational Sciences, Mustang Bio
Track: Focus Day: Alternative CAR Strategies
Date and Time: Friday, September 7, 2018, 1 p.m. EDT
Details on the poster presentation are as follows:

Title: Considerations for the Industrialization of a Phase 1 Academic CD20 CAR-T Manufacturing Process
Presenter: Suchit Sahai, Ph.D., Staff Scientist, Process Development, Fred Hutchinson Cancer Research Center
Track: Scientific Poster Session
Date and Time: Thursday, September 6, 2018, 8 a.m. EDT

Dr. Sadik Kassim, Chief Scientific Officer of Mustang Bio, will also present a plenary talk titled "From Academia to
Industry: Lessons Learned in the Development of CAR-T Therapies" during the opening ceremony on Wednesday,
September 5, 2018, at 8:45 a.m. EDT.

On September 4, 2018 Seattle Genetics, Inc. (NASDAQ:SGEN) reported that management will present at the Morgan Stanley Global Healthcare Conference on Thursday, September 13, 2018 at 2:05 p.m. EDT (Press release, Seattle Genetics, SEP 4, 2018, View Source;p=RssLanding&cat=news&id=2365825 [SID1234529344]). The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!